Publication: 3029

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 37 (22) 1876-1885
Year:
2019
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary-not-in-original
Analysis:
Primary
Data Sharing:
Alliance-data-source,-external-user
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
8
Parents:
2671  
Children:
None
Program:
TRP
Primary Committee:
Correl Sci NOS
Sec. Committees:
GI    
Pharmas:
Eli Lilly and Company, Genentech, Pfizer Inc, and Sanofi.  
Grants:
U10CA180821 and U10CA180882 (to the Alliance for Clinical Trials in Oncology), U10CA180790 (Mayo Clinic), U10CA180791 (Memorial Sloan-Kettering), U10CA180795 (Indiana University), U10CA180799 (University of Wisconsin), U10CA180830 (USC Norris Cancer Hospital), U10CA180836 (University of Chicago), U10CA180838 (University of North Carolina), U10CA180850 (The Ohio State University), U10CA180867 (Dana-Farber Cancer Institute), and U10CA180888 (Southwest Oncology Group).  
Corr. Author:
 
Authors:
                               
Networks:
CA011, CA824, LAPS-MA036, LAPS-MN026, LAPS-NC007, LAPS-OH007, OR013   
Study
Alliance-A151425
Multiple Studies, or Legacy Studies in Alliance Study:
CALGB-80405
Phases:
N/A, 3
Keywords:
ORIGINAL REPORTS, Gastrointestinal Cancer